PMDA drug package insert
タプロス点眼液0.0015％
PMDA Prescription drug · 参天製薬株式会社 · package insert Mar 15, 2024
Key facts
| Brand names | タプロス点眼液0.0015％, タプロスミニ点眼液0.0015％ |
|---|---|
| Nonproprietary names | タフルプロスト |
| Companies | 製造販売元／参天製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | プロスタグランジンF2α誘導体; 緑内障・高眼圧症治療剤 |
| Therapeutic category codes | 871319 |
| YJ codes | 1319756Q1022, 1319756Q2029 |
| Approval numbers | 22000AMX02366, 22500AMX00003 |
| Package insert edition | 第1版 |
| Package insert date | Mar 15, 2024 |
| PMDA document key | 300237_1319756Q1022_1 |
| PMDA company code | 300237 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: